美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

KraneShares China Alpha Index ETF

33.07

+0.01000.03%

盤後：33.070.00000.00%16:10 EDT

成交量：200

成交額：6,651

市值：330.72萬

市盈率：- -

高：33.07

開：33.06

低：33.07

收：33.06

52周最高：40.84

52周最低：30.00

股本：10.00萬

流通股本：10.00萬

量比：0.30

換手率：0.20%

股息：10.72

股息率：32.40%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘本月初正式進入港股通名單

港股異動 | 德適-B(02526)最高升逾14% 與安診兒訂立合作框架協議共同探索「醫療數據資產化」核心方向

新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？

港股異動 | 百奧賽圖-B(02315)升逾6% 行業景氣度持續高漲動物模型及臨床前藥效業務維持高增

港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准

港股異動 | 華寶國際午後升逾12%，國內HNB監管框架進一步成型，煙用香精業務有望受益

港股異動 | 三葉草生物-B(02197)午後升逾6% 呼吸道聯合疫苗澳洲II期臨床獲積極數據

港股諾誠健華升逾15%，近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床。

港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%

港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果並已啓動3期臨床

港股異動 | 君實生物(01877)升逾3% 兩款雙特異性抗體新藥均計劃在年內啓動關鍵III期臨床研究

港股異動 | 翰森製藥(03692)漲近4% 瑞康立伏妥塔單抗的中位OS達到18.5個月

港股異動 | 零跑汽車(09863)午後漲近6% 連續兩月銷量突破10萬輛公司上調海外銷量指引

港股異動丨俊知集團一度飆升超70%，擬購光纖產品產銷公司

港股芯片股午後走低

港股芯片股午後走低，江波龍跌超10%，兆易創新、天數智芯跌超5%，瀾起科技、壁仞科技跌超4%。

港股異動 | 煤炭股普遍走低動力煤港口價格顯出回落跡象機構指市場供應偏緊格局未改

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

港股異動 | CRO概念股漲幅居前、凱萊英大漲12%，中報持續驗證行業高景氣，多家公司上調業績指引

港股大模型雙雄大跌新融資與海外巨頭「減速」信號衝擊

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/KCAI/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KCAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KCAI\",,,,,undefined,":{"symbol":"KCAI","market":"US","secType":"STK","nameCN":"KraneShares China Alpha Index ETF","latestPrice":33.07,"timestamp":1789588800000,"preClose":33.06,"halted":0,"volume":200,"hourTrading":{"tag":"盘后","latestPrice":33.07,"preClose":33.07,"latestTime":"16:10 EDT","volume":6,"amount":198.40002,"timestamp":1789589404265,"change":0,"changeRate":0,"amplitude":0.000302},"delay":0,"changeRate":0.00030248033877791923,"floatShares":100005,"shares":100005,"eps":0,"marketStatus":"盤後交易","change":0.01,"latestTime":"09-16 17:31:18 EDT","open":33.06,"high":33.07,"low":33.07,"amount":6651,"amplitude":0,"askPrice":49.6,"askSize":200,"bidPrice":27.44,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":33.06,"sharesOutstanding":250002,"nav":33.3,"aum":3330356.18,"dividendRate":0.324034,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.07,"preClose":33.07,"latestTime":"16:10 EDT","volume":6,"amount":198.40002,"timestamp":1789589404265,"change":0,"changeRate":0,"amplitude":0.000302},"volumeRatio":0.301841},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KCAI\",,,,,undefined,":{"symbol":"KCAI","floatShares":100005,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.301841,"shares":100005,"dividePrice":10.7158,"high":33.07,"amplitude":0,"preClose":33.06,"low":33.07,"week52Low":30,"pbRate":"--","week52High":40.84,"institutionHeld":0,"latestPrice":33.07,"committee":-0.333333,"eps":0,"divideRate":0.324034,"volume":200,"delay":0,"ttmEps":0,"open":33.06,"prevYearClose":30.48,"prevWeekClose":33.22,"prevMonthClose":33.259,"prevQuarterClose":32.15,"fiveDayClose":33.3072,"twentyDayClose":32.98,"sixtyDayClose":32.6999},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KCAI\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"KCAI","amount":0.080552,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2025-12-31"},{"date":"2025-12-22","symbol":"KCAI","amount":10.716664,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KCAI","amount":0.59272,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KCAI\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-18","value":0.59272,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-23","value":10.716664,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2025-12-31","value":0.080552,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KCAI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KCAI\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667492656","title":"港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘 本月初正式進入港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2667492656","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667492656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:52","pubTimestamp":1789372341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亮晴控股盘中涨超31%。消息面上，上交所近期宣布调整沪港通下港股通标的，亮晴控股正式进入港股通名单，已于9月7日起生效。值得注意的是，6月30日，亮晴控股成功从GEM转至主板上市。公司转主板两月有余便进入港股通名单，有助于进一步优化投资者结构、提升股票流动性及企业品牌价值。值得一提的是，今年7月，亮晴控股“AI抗衰老”平台开发启动，委聘香港AI企业Sunseeker开发模型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","KCAI","03774","BK4588","BK1215","BK4585","FLHK","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656224","title":"港股異動 | 德適-B(02526)最高升逾14% 與安診兒訂立合作框架協議 共同探索 「醫療數據資產化」 核心方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656224?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:49","pubTimestamp":1789372174,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德适-B最高涨超14%，截至发稿，涨7.25%，报509港元，成交额7412.57万港元。消息面上，9月11日，德适-B发布公告，本公司与浙江省安诊儿医学人工智能科技有限公司(安诊儿)订立合作框架协议，围绕医学影像人工智能、基层影像云服务及医疗数据产品开展合作，合作期限自签订之日起为三年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","159891","BK1100","KCAI","VXUS","02526","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765505","title":"新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765505?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:36","pubTimestamp":1789371362,"startTime":"0","endTime":"0","summary":"近日，普莱医药向港交所主板递交上市申请，中信证券担任独家保荐人，这是公司继2月13日首次提交上市申请后的第二次递表。目前的治疗药物以唑类抗真菌药为主，但耐药性问题同样存在。目前该产品正在中国进行一项II期临床试验，且已获FDA批准在美国进行一项II期临床试验。整体来看，在全球抗生素耐药性问题日益严峻的背景下，抗菌肽作为新型抗感染药物具备广阔的市场前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1515","KCAI","BK1161","BK1574","BK4588","159938","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667554306","title":"港股異動 | 百奧賽圖-B(02315)升逾6% 行業景氣度持續高漲 動物模型及臨床前藥效業務維持高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554306","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:31","pubTimestamp":1789371077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超6%，截至发稿，涨6.24%，报59.6港元，成交额8729.41万港元。消息面上，今年上半年，百奥赛图实现营收9.4亿元，同比增长51.6%；归母净利润2.4亿元，同比大增402%。与此同时，本月初，百奥赛图宣布与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发。中邮证券指出，行业景气度持续高涨叠加海外拓展共振，动物模型+临床前药效业务维持高增。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","BK4585","BK0216","BK4588","VXUS","KCAI","688796","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667563655","title":"港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667563655","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667563655?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:18","pubTimestamp":1789370281,"startTime":"0","endTime":"0","summary":"消息面上，9月11日，沛嘉医疗-B发布公告，公司自主研发的GeminiOne经导管缘对缘修复系统近期已获中华人民共和国国家药品监督管理局批准其注册申请。GeminiOne获批标志着集团正式进入二尖瓣反流的商业化治疗领域，并代表集团在主动脉瓣狭窄及主动脉瓣反流治疗既有布局的基础上，进一步显著扩充其经导管瓣膜治疗产品组合。GeminiOne之EU MDR CE标志注册申请已提交，而美国早期可行性研究现正进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK4588","KCAI","BK1583","BK4585","BK1100","VXUS","BK1574","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658043","title":"港股異動 | 華寶國際午後升逾12%，國內HNB監管框架進一步成型，煙用香精業務有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658043","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658043?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华宝国际午后涨超12%。兴业证券指出，意见稿首次明确烟支、烟具和气溶胶具体要求，国内HNB监管框架进一步成型。东北证券指出，国内卷烟市场需求增长面临较大压力，因此HNB放开提上日程成为挽救国内烟草市场的必选项。加热卷烟国标公开征求意见，标志着中国HNB产业从“政策模糊期”迈入“规则明确期”。HNB和口含烟的发展带来新的香精需求，有利于公司烟用香精业务的发展。","market":"fut","thumbnail":"https://static.tigerbbs.com/2b916287cbff73b370c1a2e0a155be73","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2b916287cbff73b370c1a2e0a155be73"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495549.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华宝国际午后涨超12%，国内HNB监管框架进一步成型，烟用香精业务有望受益","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","00336","VXUS","BK1129","BK4585","BK1580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667965362","title":"港股異動 | 三葉草生物-B(02197)午後升逾6% 呼吸道聯合疫苗澳洲II期臨床獲積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667965362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667965362?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:54","pubTimestamp":1789368871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三叶草生物-B午后涨超6%。截至发稿，涨5.24%，报2.01港元，成交额548.61万港元。消息面上，三叶草生物近期宣布，其呼吸道联合疫苗候选产品SCB-1022和SCB-1033在澳大利亚老年人群中开展的II期临床试验获得积极初步数据。此外，公司已完成SCB-1022/1033相关抗原组分2000L生物反应器商业规模生产放大，并完成多个批次。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","KCAI","BK1161","02197","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667535356","title":"港股諾誠健華 升逾15%，近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667535356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667535356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:49","pubTimestamp":1789368572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KCAI","VXUS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658657","title":"港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","KCAI","ORR","BK4588","LU2543165471.USD","HK0000252160.HKD","HK0000500386.USD","BK4585","HK0000252152.HKD","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果 並已啓動3期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658010?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","MDTX","BK1161","BK4588","LU0196878994.USD","PSYK","IBBQ","KCAI","VXUS","IBBJ","BMED","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658586","title":"港股異動 | 君實生物(01877)升逾3% 兩款雙特異性抗體新藥均計劃在年內啓動關鍵III期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658586","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:15","pubTimestamp":1789366522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报17.11港元，成交额1995.51万港元。消息面上，9月14日，君实生物在2026年半年度业绩说明会上披露核心创新药管线的最新研发进展。公司明确表示，两款备受关注的双特异性抗体新药均计划在2026年内启动关键的III期临床研究。其中，靶向CD20/CD3的双抗药物JS203将正式进入III期临床阶段；而另一款靶向PD-1/VEGF的双抗药物JS207目前正处于II期临床研究阶段，正在多个瘤种中积极开展与化疗、单抗及ADC等不同治疗手段的联合用药探索，并同样预计于2026年内启动III期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4585","BK1515","BK1161","VXUS","BK1583","BK4588","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667630269","title":"港股異動 | 翰森製藥(03692)漲近4% 瑞康立伏妥塔單抗的中位OS達到18.5個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667630269","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667630269?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:58","pubTimestamp":1789365528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨近4%，截至发稿，涨3.73%，报33.94港元，成交额2.05亿港元。消息面上，9月13日，翰森制药在2026世界肺癌大会首场主席论坛上，以最新突破性摘要形式口头报告自研B7-H3靶向ADC——瑞康立伏妥塔单抗的III期ARTEMIS-008研究期中结果。这次公布的数据，瑞康立伏妥塔单抗刷新了小细胞肺癌二线治疗最长总生存期纪录。具体看，瑞康立伏妥塔单抗的中位OS达到18.5个月，而托泊替康的中位OS是10.3个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","KCAI","03692","BK4588","VXUS","BK1191","BK4585","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667630605","title":"港股異動 | 零跑汽車(09863)午後漲近6% 連續兩月銷量突破10萬輛 公司上調海外銷量指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667630605","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667630605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:57","pubTimestamp":1789365435,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，零跑汽车午后涨近6%。消息面上，零跑汽车8月销量103129辆，同比增长80.7%，环比增长1.8%，连续两月销量突破10万辆并再创历史新高。中信建投则表示，公司积极上调海外销量指引至2026全年稳步完成海外销量15万辆，挑战20万辆；2027年海外销量目标35-40万辆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09863","BK4588","VXUS","BK1119","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667302406","title":"港股異動丨俊知集團一度飆升超70%，擬購光纖產品產銷公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2667302406","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667302406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:57","pubTimestamp":1789365421,"startTime":"0","endTime":"0","summary":"俊知集团(1300.HK)上午盘中一度飙升超70%至3.465港元，股价创6月以来新高，截至目前成交额放大至1.7亿港元。消息面上，公司宣布，拟收购青海中利光纤技术100%股权，代价4.55亿元。目标公司主要从事光纤预制棒、光纤及光纤接插件的生产及销售。而目标附属公司则主要从事光纤预制棒、光纤、光纤接插件的研究与开发。董事会预期，于签订《产权交易合同》后，收购事项将根据上市规则第14章构成公司的须予披露交易。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/14/20260914712863.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/14/20260914712863.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32368841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["VXUS","KCAI","BK4585","BK1149","BK4588","BK1506","01300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667163099","title":"港股芯片股午後走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2667163099","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667163099?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:52","pubTimestamp":1789365157,"startTime":"0","endTime":"0","summary":"港股芯片股午后走低","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873328636.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873328636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XSEM","BK4588","BK4585","VXUS","KCAI","BERZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667557630","title":"港股芯片股午後走低，江波龍跌超10%，兆易創新、天數智芯跌超5%，瀾起科技、壁仞科技跌超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667557630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667557630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:47","pubTimestamp":1789364877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","KCAI","BK4588","XSEM","BERZ","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667305630","title":"港股異動 | 煤炭股普遍走低 動力煤港口價格顯出回落跡象 機構指市場供應偏緊格局未改","url":"https://stock-news.laohu8.com/highlight/detail?id=2667305630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667305630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:42","pubTimestamp":1789364534,"startTime":"0","endTime":"0","summary":"消息面上，近期动力煤港口价格显出回落迹象，产地煤价涨跌互现。煤炭资源网数据显示，截至9月11日，秦皇岛港Q5500动力煤市场价报收于984元/吨，周环比上涨42元/吨，但9月11日环比下降1元/吨。国联民生证券认为，本轮下跌更多是对前期超涨的修正，市场供应偏紧格局未改。供给端安监高压持续，产地供给仍受限。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00866","BK4588","COAL","161032","01171","BK1225","KCAI","03668","BK1178","BK4585","BK1594","VXUS","00639","BK1538","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","LU0455707207.USD","IE00B543WZ88.USD","IBBQ","BK1589","KURE","LU2476274720.SGD","LU0348767384.USD","LU2476274308.USD","01177","LU0244354667.USD","BK1191","LNGR","LU0348735423.USD","LU0348766576.USD","LU0417516738.SGD","MEDX","159992","LU0348827113.USD","HK0000165453.HKD","LU2488822045.USD","VXUS","LU1961090484.USD","LU2097828557.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348825331.USD","01530","KCAI","LU2778985437.USD","06978","BK1593","LU0607220059.USD","09926","LU1969619763.USD","LU0634319403.HKD","LU2097828805.USD","LU0326950275.SGD","LU1188198961.HKD","BK1574","BK1521","LU0561508036.HKD","BK4588","IE00BZ08YR35.GBP","01801","LU0348784397.USD","LU2097828714.EUR","BK1161","LU1831875114.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667763172","title":"港股異動 | CRO概念股漲幅居前、凱萊英大漲12%，中報持續驗證行業高景氣，多家公司上調業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667763172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667763172?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:34","pubTimestamp":1789364090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，凯莱英涨5.89%，报142.1港元；康龙化成涨4.72%，报28.84港元；泰格医药涨4.64%，报43.32港元；药明生物涨2.30%，报48.08港元。消息面上，国内外CXO公司中报业绩持续验证行业高景气。国内药明康德发布中报，业绩大幅超市场预期，同时大幅上调全年业绩指引。该行表示，看好药明系、康龙化成、凯莱英、泰格医药及金斯瑞。","market":"sh","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495468.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | CRO概念股涨幅居前，中报持续验证行业高景气，多家公司上调业绩指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK1521","BK1141","LU0326950275.SGD","LU1720050803.USD","02269","SG9999002463.SGD","LU0029874061.USD","06821","LU0823426308.USD","LU0979878070.USD","LU0181495838.USD","LU0823426480.USD","03347","LU0417516738.SGD","LU0456827905.SGD","LU2039709279.SGD","LU0561508036.HKD","LU0039217434.USD","BK1589","LU0819121731.USD","LU0348735423.USD","BK1191","KURE","LU1688375341.USD","LU3063872942.SGD","BK4588","LU0140636845.USD","LU0359201612.USD","LU0516423091.SGD","03759","LU0320764599.SGD","LU1880383366.USD","LU0588546209.SGD","KCAI","LU0456846285.SGD","LU0516423174.USD","LU0327786744.USD","LU0516422366.SGD","LU0307460666.USD","LU0348825331.USD","LU0856984785.SGD","LU0359202008.SGD","LU0516422952.EUR","LU0572944931.SGD","BK1583","LU0051755006.USD","LU0348827113.USD","LU0128526141.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637532","title":"港股大模型雙雄大跌 新融資與海外巨頭「減速」信號衝擊","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637532","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637532?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 12:43","pubTimestamp":1789361029,"startTime":"0","endTime":"0","summary":"【港股大模型双雄大跌 新融资与海外巨头“减速”信号冲击】9月14日，港股开盘，恒生科技指数低开，AI概念股承压。消息面上，9月13日，智谱发布约50亿美元新融资公告，另美国头部模型厂商OpenAI与Anthropic同日发出“减速”信号，强调在模型递归式自我改进（RSI）趋势下，厂商需要放缓节奏，优先投入可监测性、对齐等方面。相关因素叠加，引发港股AI板块集体调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873273784.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873273784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WISE","KCAI","VXUS","GPTZ","LRNZ","BK4588","BK4585","EPAI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":8,"totalSize":668,"code":"91000000","status":"200"}]}}